Development of a two-site immunoassay of recombinant urate oxidase (SR 29142) and its use for determination of pharmacokinetic parameters in rats and baboons

J Pharm Sci. 1996 Sep;85(9):955-9. doi: 10.1021/js960009s.

Abstract

Two monoclonal antibodies (Mabs), 12C7 and 11G11, both directed against recombinant urate oxidase (SR 29142), were selected for their epitope specificity to develop a two-site immunoassay of urate oxidase in plasma. A quantitative recovery of urate oxidase in plasma was obtained at all the concentrations tested, and the limit of quantification was found to be 0.5 ng/mL. Intra-and interassay coefficients of variation ranged from 1.2 to 6.7% and from 3.5 to 10.8%, respectively. The specificity of the two antibodies was studied in Western-blot experiments. This assay was used successfully to determine urate oxidase pharmacokinetic parameters after intravenous injection in rats and baboons. In these two species, urate oxidase pharmacokinetics was characterized by a low clearance and a low volume of distribution without gender difference.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Female
  • Immunoassay
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Papio
  • Rats
  • Rats, Sprague-Dawley
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Urate Oxidase / analysis
  • Urate Oxidase / immunology
  • Urate Oxidase / pharmacokinetics*

Substances

  • Antibodies, Monoclonal
  • Urate Oxidase